Q5158 Injection, denosumab-bnht, 1 milligrams
Also known as: denosumab biosimilar, RANKL inhibitor, osteoporosis drug
Injection of denosumab-bnht (Prolia), a biosimilar to denosumab, administered at 1 milligram per dose.
In Plain Language
bone density increase injection; osteoporosis prevention; fracture prevention
Clinical Context
Used for osteoporosis treatment in postmenopausal women and men at high fracture risk. Administered subcutaneously every 6 months as monoclonal antibody RANKL inhibitor.
RVU Information
CPT Q5158 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5158?
CPT Q5158 (Injection, denosumab-bnht, 1 milligrams) is a Q Codes code. Injection of denosumab-bnht (Prolia), a biosimilar to denosumab, administered at 1 milligram per dose.
Is Q5158 covered by insurance?
Q5158 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for osteoporosis treatment in postmenopausal women and men at high fracture risk. Administered subcutaneously every 6 months as monoclonal antibody RANKL inhibitor.
When is CPT Q5158 used?
Used for osteoporosis treatment in postmenopausal women and men at high fracture risk. Administered subcutaneously every 6 months as monoclonal antibody RANKL inhibitor.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.